Is bone alkaline phosphatase an adequate marker of bone metabolism during acute corticosteroid treatment?

Clinical Chemistry

Volumn 42, Issue 1, 1996, Pages 102-103

  Peretz, Anne ^a   Moris, Muriel ^a   Willems, Dominique ^a   Bergmann, Pierre ^a  

^a BRUGMANN UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; METHYLPREDNISOLONE; OSTEOCALCIN; PROCOLLAGEN;

ARTICLE; BONE METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORTICOSTEROID THERAPY; HUMAN; IMMUNORADIOMETRIC ASSAY; INTRAVENOUS DRUG ADMINISTRATION; OSSIFICATION; RADIOIMMUNOASSAY; RHEUMATIC DISEASE;

EID: 0030034440     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/42.1.102     Document Type: Article

References (14)

1. Adler RA, Rosen CJ. Corticosteroids and osteoporosis. Endocrinol Metab Clin North Am 1994;3:641-54.
2. Hodsman AB, Toogood JH, Jennings B, Fraher LJ, Baskerville JC. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab 1991;72:530-40.
3. Peretz A, Praet JP, Bosson D, Rozenberg S, Bourdoux P. Serum osteocalcin in the assessment of corticosteroid induced osteoporosis. Effect of long and short term corticosteroid treatment. J Rheumatol 1989;16:363-7.
4. Cosman F, Nieves J, Herbert J, Shen V, Lindsay R. High-dose glucocorticoids in multiple sclerosis patients exert direct effects on the kidney and skeleton. J Bone Miner Res 1994;9:1097-105.
5. Lems WF, Jacobs JWG, Van Den Brink HR, Van Rijn HJM, Bijlsma JWJ. Transient decrease in osteocalcin and markers of type I collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis. Br J Rheumatol 1993;32:787-9.
6. Garnerero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 1994;79:1693-700.
7. Hassager C, Risteli J, Risteli L, Jensen SB, Christiansen C. Diurnal variation in serum markers of type I collagen synthesis and degradation in healthy postmenopausal women. J Bone Miner Res 1992;7:1307-11.
8. Ebeling PR, Peterson JM, Riggs BL, Utility of type I collagen propeptide assays for assessing abnormalities in metabolic bone diseases. J Bone Miner Res 1992;7:1243-50.
9. Garnero P, Delmas P. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 1993;77:1046-53.
10. Prummel MF, Wiersinga WM, Lips P, Sanders GTB, Sauerwein HP. The course of biochemical parameters of bone turnover during treatment with corticosteroids. J Clin Endocrinol Metab 1991;72:382-6.
11. Subramaniam M, Colvard D, Keeting PE, Rasmussen K, Riggs BL, Spemsberg TC. Glucocorticoid regulation of alkaline phosphatase, osteocalcin, and proto-oncogenes in normal osteoblast-like cells. J Cell Biochem 1992;50: 411-24.
12. Kream BE, Petersen DN, Raisz LG. Cortisol enhances the anabolic effects of insulin-like growth factor I on collagen synthesis and procollagen messenger ribonucleic acid level in 21-day fetal rat calvariae. Endocrinology 1990;126: 1576-83.
13. Walton RJ, Preston CJ, Russell RGG, Kanis JA. An estimate of the turnover rate of bone-derived plasma alkaline phosphatase in Paget's disease. Clin Chim Acta 1975;63:227-9.
14. Farley JR, Hall SL, Flacas D, Orcutt C, Miller BE, Hill CS, Baylink DJ. Quantification of skeletal alkaline phosphatase in osteoporotic serum by wheat germ agglutinin precipitation, heat inactivation, and a two-site immunoradiometric assay. Clin Chem 1994;40:1749-56.